BeiGene takes a new approach to a hot target
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
The company dribbles out more data on IMA203, and the numbers head in the right direction.
PRAME has become a hot target for Immatics, which is now clinically progressing two different modalities against this antigen.